218 related articles for article (PubMed ID: 23831594)
1. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
Antrobus RD; Berthoud TK; Mullarkey CE; Hoschler K; Coughlan L; Zambon M; Hill AV; Gilbert SC
Mol Ther; 2014 Jan; 22(1):233-8. PubMed ID: 23831594
[TBL] [Abstract][Full Text] [Related]
2. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
Mullarkey CE; Boyd A; van Laarhoven A; Lefevre EA; Veronica Carr B; Baratelli M; Molesti E; Temperton NJ; Butter C; Charleston B; Lambe T; Gilbert SC
Eur J Immunol; 2013 Jul; 43(7):1940-52. PubMed ID: 23589155
[TBL] [Abstract][Full Text] [Related]
3. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais ME; Duncan CJ; Sheehy SH; Havelock T; Faust SN; Williams RL; Gilbert A; Oxford J; Dong T; Hill AV; Gilbert SC
Clin Infect Dis; 2012 Jul; 55(1):19-25. PubMed ID: 22441650
[TBL] [Abstract][Full Text] [Related]
4. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
Antrobus RD; Lillie PJ; Berthoud TK; Spencer AJ; McLaren JE; Ladell K; Lambe T; Milicic A; Price DA; Hill AV; Gilbert SC
PLoS One; 2012; 7(10):e48322. PubMed ID: 23118984
[TBL] [Abstract][Full Text] [Related]
5. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
Mullin J; Ahmed MS; Sharma R; Upile N; Beer H; Achar P; Puksuriwong S; Ferrara F; Temperton N; McNamara P; Lambe T; Gilbert SC; Zhang Q
Vaccine; 2016 Mar; 34(14):1688-95. PubMed ID: 26902548
[TBL] [Abstract][Full Text] [Related]
6. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
Powell TJ; Peng Y; Berthoud TK; Blais ME; Lillie PJ; Hill AV; Rowland-Jones SL; McMichael AJ; Gilbert SC; Dong T
PLoS One; 2013; 8(5):e62778. PubMed ID: 23658773
[TBL] [Abstract][Full Text] [Related]
7. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
[TBL] [Abstract][Full Text] [Related]
8. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
Berthoud TK; Hamill M; Lillie PJ; Hwenda L; Collins KA; Ewer KJ; Milicic A; Poyntz HC; Lambe T; Fletcher HA; Hill AV; Gilbert SC
Clin Infect Dis; 2011 Jan; 52(1):1-7. PubMed ID: 21148512
[TBL] [Abstract][Full Text] [Related]
9. A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol.
Swayze H; Allen J; Folegatti P; Yu LM; Gilbert S; Hill A; Ellis C; Butler CC
F1000Res; 2019; 8():719. PubMed ID: 32089822
[TBL] [Abstract][Full Text] [Related]
10. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
Front Immunol; 2018; 9():3103. PubMed ID: 30761157
[TBL] [Abstract][Full Text] [Related]
12. Modified Vaccinia Ankara-Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue.
Puksuriwong S; Ahmed MS; Sharma R; Krishnan M; Leong S; Lambe T; McNamara PS; Gilbert SC; Zhang Q
J Infect Dis; 2020 Aug; 222(5):807-819. PubMed ID: 31740938
[TBL] [Abstract][Full Text] [Related]
13. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
Boyd AC; Ruiz-Hernandez R; Peroval MY; Carson C; Balkissoon D; Staines K; Turner AV; Hill AV; Gilbert SC; Butter C
Vaccine; 2013 Jan; 31(4):670-5. PubMed ID: 23200938
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
[TBL] [Abstract][Full Text] [Related]
15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line.
Folegatti PM; Bellamy D; Flaxman A; Mair C; Ellis C; Ramon RL; Ramos Lopez F; Mitton C; Baker M; Poulton I; Lawrie A; Roberts R; Minassian A; Ewer KJ; Evans TG; Hill AVS; Gilbert SC
Vaccines (Basel); 2019 Mar; 7(1):. PubMed ID: 30909516
[TBL] [Abstract][Full Text] [Related]
17. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
[TBL] [Abstract][Full Text] [Related]
18. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
[TBL] [Abstract][Full Text] [Related]
20. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.
Zhirnov OP; Isaeva EI; Konakova TE; Thoidis G; Piskareva LM; Akopova II; Kartashov A; Altstein AD; Ilyinskii PO; Shneider AM
Influenza Other Respir Viruses; 2007 Mar; 1(2):71-9. PubMed ID: 18784792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
